US20060134065A1 - Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use - Google Patents

Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use Download PDF

Info

Publication number
US20060134065A1
US20060134065A1 US10/559,431 US55943105A US2006134065A1 US 20060134065 A1 US20060134065 A1 US 20060134065A1 US 55943105 A US55943105 A US 55943105A US 2006134065 A1 US2006134065 A1 US 2006134065A1
Authority
US
United States
Prior art keywords
polyprotein
expression vector
ns5b
expression
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/559,431
Other languages
English (en)
Inventor
Anne Fournillier
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Institut National de la Sante et de la Recherche Medicale INSERM
Original Assignee
Transgene SA
Institut National de la Sante et de la Recherche Medicale INSERM
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene SA, Institut National de la Sante et de la Recherche Medicale INSERM filed Critical Transgene SA
Assigned to TRANSGENE S.A., INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE reassignment TRANSGENE S.A. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: ABRAHAM, JEAN-DANIEL, DIMITROVA-TCHOMAKOV, MARIE, PARNOT, MARIE, FOURNILLIER, ANNE, INCHAUSPE, GENEVIEVE
Publication of US20060134065A1 publication Critical patent/US20060134065A1/en
Priority to US11/723,638 priority Critical patent/US7695960B2/en
Priority to US12/472,330 priority patent/US8057162B2/en
Priority to US13/241,578 priority patent/US8541004B2/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to the field of prophylactic and therapeutic vaccination directed against the hepatitis C virus (HCV). It relates in particular to a novel composition containing a polyprotein corresponding to the two colinear proteins NS3 and NS4 (hereafter called polyprotein NS3/NS4) and a polypeptide constituted by NS5b, the vectors, such as adenovirus or poxvirus, capable of expressing this composition and their use as vaccine.
  • HCV hepatitis C virus
  • Hepatitis C is the major cause of transfusion-acquired hepatitis. Hepatitis C can also be transmitted by other percutaneous routes, for example by injection of drugs by intravenous route. The risk of contamination of health professionals is moreover not negligible. Sexual transmission has been described.
  • Hepatitis C differs from other forms of liver diseases associated with viruses, such as hepatitis A, B or D.
  • the infections by the hepatitis C virus (HCV or HCV) are mostly chronic resulting in diseases of the liver, such as hepatitis, cirrhosis and carcinoma in a large number of cases (5 to 20%) and represents 30% of the hepatic transplants in developed countries.
  • HCV infections therefore exist (estimated at between 5 and 10%), known as sporadic infections, the etiology of which is unknown and which cannot be controlled.
  • HCV was the first hepatotropic virus isolated by means of molecular biology techniques. The viral genome sequences were cloned before the viral particle was visualized.
  • HCV belongs to a new genus of the Flaviviridae family, the hepaciviruses. It is a positive single-strand RNA virus, of 9.5 kb, which is replicated by a complementary RNA copy and the translation product of which is a polyprotein precursor of approximately 3,000 amino acids.
  • the 5′ end of the HCV genome corresponds to an untranslated region adjacent to the genes that code for the structural proteins, the core protein of the nucleocapsid, the two envelope glycoproteins, EI and E2, and a small protein called p7.
  • the 5′ untranslated region and the gene core are relatively well preserved in the different genotypes.
  • the envelope proteins EI and E2 are encoded by regions that are more variable from one isolate to another.
  • the protein p7 is an extremely hydrophobic protein, which may constitute an ion channel.
  • the 3′ end of the HCV genome contains the genes that code for the non-structural proteins (NS2, NS3, NS4, NS5) and for a 3′ non-coding region possessing a well-conserved domain (Major M E, Feinstone S M, Hepatology, June 1997, 25 (6): 1527-1538).
  • the most effective therapy for the treatment of hepatitis C combines pegylated interferon and ribavin (Manns M P et al., The Lancet, 22nd Sep. 2001, Vol. 358, 958-965). Whilst this therapy is particularly effective in the case of patients infected by viral strains belonging to the genotypes 2 and 3, it still has only a limited effect on the genotypes 1a, 1b and 4 (Manns M P, op. cit.). Less than 50% of the treated patients become “long-term responders”. Moreover, this therapy is an expensive intervention (10,000 to 15,000 euros/patient/year) and is associated with toxic effects. In fact, 5 to 10% of the patients are obliged to stop treatment before the end.
  • the molecules of the major histocompatibility complex are referred to as class I or class II.
  • the class I molecules are expressed on virtually all of the nucleated cells and are able to present epitopes or peptides to the CD8 + cytotoxic T lymphocytes (CTL).
  • CTL cytotoxic T lymphocytes
  • the class II molecules are able to present epitopes to the CD4 + T cells, but their expression is restricted to antigen-presenting cells.
  • the vaccines against the hepatitis C virus currently envisaged are based on the use of adjuvant recombinant proteins, peptides, expression vectors among which there can be mentioned vectors of viral or bacterial origin or of naked DNA.
  • adjuvant recombinant proteins, peptides, expression vectors among which there can be mentioned vectors of viral or bacterial origin or of naked DNA.
  • one or more viral proteins or one or more genes coding for these viral proteins are used.
  • viral proteins or one or more genes coding for these viral proteins are selected, the latter are often constituted either by some or all of the structural proteins (Makimura et al., 1996, Vaccine, 14: 28-34; Fournilier A. et al., 1999, J. Virology, 73: 7497-7504), or by individual non-structural proteins or comprising at least two contiguous proteins (Brinster et al., 2001, Hepatology, 34: 1206-1217), or by a mixture of structural and non-structural proteins (Pancholi et al., 2003, J. Virology, 77: 382-390).
  • Patent Application WO99/38880 describes the use of three genes coding separately for the three proteins NS3, NS4 and NS5 (a and b) in a vaccine composition comprising three DNA vaccines each expressing these three proteins separately.
  • the authors show the induction of T lymphocytes specific to the three antigens in mice. Only the vaccine expressing NS5a and b has been tested in vivo in a protection test.
  • Patent Application WO01/30812 describes the use of a fusion protein constituted by the non-structural proteins NS3, NS4 and NS5a, if necessary in combination with the non-structural protein NS5b. The authors have indicated that this combination made it possible to activate the HCV-specific T cells.
  • This Patent Application simply describes the ability of vaccine formulations (naked-DNA, recombinant-adenovirus or recombinant-vaccinia-virus type) expressing the fusion protein NS3, NS4, NS5a or the protein NS5a to induce specific immune responses mediated by specific T lymphocytes.
  • an object of the present invention is a peptide composition
  • a peptide composition comprising a polyprotein NS3/NS4 of the hepatitis C virus, as well as a polypeptide NS5b of the hepatitis C virus.
  • An object of the invention is also the vectors including the nucleotide sequences coding for this peptide composition, such as the adenoviruses and poxviruses, as well as microorganisms or host cells transformed by these vectors.
  • An object of the invention is finally the antibodies directed against the peptide composition of the invention, as well as the use of the peptide composition, vectors and antibodies for the preparation of a medicament intended for the inhibition or control of an infection caused by the hepatitis C virus, and in a vaccine composition.
  • the present invention therefore proposes a novel peptide composition constituted by a polyprotein NS3/NS4 and a polypeptide NS5b of HCV, which composition has the ability to stimulate a cell-mediated immune response specific to HCV, such that it is useful in the field of prophylactic and therapeutic vaccination directed against the hepatitis C virus.
  • the polyprotein NS3/NS4 of the peptide composition of the invention is constituted by the protein NS3 and the protein NS4a and b, without interruption in the peptide sequence, as in the native polyprotein.
  • the HCV genome contains a single open reading frame that is transcribed into a polyprotein. This HCV polyprotein can be cleaved in order to produce at least ten distinct parts, in the order NH 2 -Core-EI-E2-p7-NS2-NS3-NS4a-NS4b-NS5a-NS5b-COOH.
  • the protein NS3 is a protein of 630 amino acids, which appears approximately from amino acid 1027 to amino acid 1657 of the polyprotein.
  • the polyprotein NS3/NS4 therefore appears approximately from amino acid 1027 to amino acid 1972.
  • polypeptide NS5b also contained in the composition of the invention, it is constituted by 590 amino acids and appears approximately from amino acid 2421 to amino acid 3011 of the polyprotein (Choo et al., 1991, op. cit.).
  • the protein NS3 comprises two distinct structural domains, namely an N-terminal domain endowed with an active serine protease activity that is involved in the maturation of the viral polyprotein, and a C-terminal domain comprising a helicase activity associated with an NTPase activity that plays a role in the replication of the viral genome.
  • polyprotein NS3/NS4 and “polypeptide NS5b”, is of course meant the polyproteins and polypeptides having the native amino acid sequences, originating from any HCV strain and isolate, as well as their analogues, muteins and homologues.
  • analogues or “muteins” of the polyprotein and of the polypeptide, is meant the biologically active derivatives of the reference molecules that have the desired activity, namely the ability to stimulate a cell-mediated immune response as defined above.
  • analogue refers to compounds having a native polypeptide sequence and structure having one or more additions, substitutions (generally conservative in terms of nature) and/or amino acid deletions, relative to the native molecule, to the extent that the modifications do not destroy the immunogenic activity.
  • mutein is meant the peptides having one or more elements imitating the peptide (peptoids), such as those described in the Patent Application PCT WO91/04282.
  • the analogue or the mutein have at least the same immunoactivity as the native molecule. Processes for preparing polypeptide analogues and muteins are known to a person skilled in the art and are described below.
  • the particularly preferred analogues include substitutions that are conservative in nature, i.e. the substitutions, which take place in a family of amino acids.
  • the amino acids are generally divided into 4 families, namely (1) the acid amino acids such as aspartate and glutamate, (2) the basic amino acids such as lysine, arginine and histidine, (3) the non-polar amino acids such as alanine, leucine, isoleucine, proline, phenylalanine, methionine and tryptophane and (4) the polar non-charged amino acids such as glycine, asparagine, glutamine, cysteine, serine, threonine and tyrosine.
  • Phenylalanine, tryptophane and tyrosine are sometimes classified as aromatic amino acids.
  • an isolated replacement of leucine by isoleucine or valine, of an aspartate by a glutamate, of a threonine by a serine, or a similar conservative replacement of one amino acid by another amino acid having a structural relationship will not have a major effect on the biological activity.
  • a person skilled in the art will easily determine the regions of the peptide molecule of interest that can tolerate a change by referring to the Hopp/Woods and Kyte-Doolittle plots, well known in the art.
  • homology is meant the percentage of identity between two peptide molecules, such as polyproteins and polypeptides.
  • Two amino acid sequences are “more or less homologous” to each other when the sequences have at least 60%, preferably at least 75%, more preferably also at least 80-85%, more preferably also at least 90% and still more preferably at least 95-98% or more of sequence identity over a defined length of the peptide molecules.
  • identity refers to an exact amino acid to amino acid correspondence of two peptide sequences.
  • the percentage of identity can be determined by a direct comparison of the sequence information between two molecules by aligning the sequences, counting the exact number of mismatches between the two aligned sequences, dividing by the length of the shorter sequence and multiplying the result by 100.
  • the percentage of identity can also be determined using computer programs such as ALIGN, Dayhoff, M. O. in Atlas of Protein Sequence and Structure M. O. Dayhoffed., 1981, 5 Suppl., 3: 482-489.
  • nucleic acid and amino acid sequences of a certain number of HCV strains and isolates, and in particular of the protein NS3, of the protein NS4 and of the polypeptide NS5b, have already been determined.
  • the isolate HCV-J1 is described in Okamoto H. et al., 1992, Nucleic Acids Res., 20: 6410-6410.
  • the complete coding sequences of two independent HCV isolates, namely the isolates HCV-J and-BK, have been described in Kato et al., 1990, Proc. Natl. Acad., Sci., 87: 9524-9528 and in Takamizawa et al., 1991, J. Virol., 65: 1105-1113 respectively.
  • the isolate HCV-1 it is described in Choo et al., 1990, Brit. Med. Bull., 46: 423-441 and in Choo et al., 1991, op. cit.
  • the isolate HVC-H has been described in Inchauspe G. et al;, 1991, Proc. Natl. Acad. Sci., 88: 10292-10296.
  • the isolate HCV-G9 has been described in Okamoto H., et al., 1994, J. Gen. Virol., 45: 629-635.
  • the isolates HCV-J6 and -J8 have been described in Okamoto H., et al., 1991, J. Gen. Virol., 72: 2697-2704 and Okamoto H., et al., 1992, Virology, 188: 331-341 respectively.
  • the isolate HVC-BEBE1 has been described in Nako H., et al., 1996, J. Gen.
  • the isolate HCV-EUHK2 has been described in Adams A., et al., 1997, Biochem. Biophys. Res. Commun., 234: 393-396.
  • the isolates HCV-VN235, -VN405 and -VN004 have been described in Tokita H., et al., 1998, J. Gen. Virol., 79: 1847.
  • the HCV strains and isolates can have different genotypes, namely genotypes 1a (isolates HCV-1, -J1 and-H), 1b (isolates HCV-J and BK), 1c (isolate HCV-G9), 2a (isolate HCV-J6), 2b (isolate HCV-J8), 2c (isolate HCV-BEBE1), 3a (isolate HCV-NZL1), 3b (isolate HCV-Tr), 4a (isolate HCV-ED43), 5a (isolate HCV-EUH1480), 6a (isolate HCV-EUHK2), 7b (isolate HCV-VN235), 8b (isolate HCV-VN405), 9a (isolate HCV-VN004), 10a (isolate HCV-JK049) and 11a (isolate HCV-JK046).
  • genotypes 1a isolates HCV-1, -J1
  • NS3 and/or NS4 and/or NS5b originate from viruses of different genotypes.
  • NS3 and/or NS4 and/or NS5b originate from viruses of the same genotype, preferably of genotype 1b.
  • polyprotein NS3/NS4 and the polypeptide NS5b contained in the peptide composition of the invention can be either of native origin, or of recombinant origin.
  • polyprotein NS3/NS4 and the polypeptide NS5b of native origin are obtained from HCV strains or isolates, by means of the use of synthetic oligonucleotide primers that will serve to amplify the native viral sequences, either from sera of patients infected by the targeted viral genotype or genotypes, or from already purified viral RNA, originating for example from patients' blood or liver, or from complementary DNA that is free or cloned beforehand in an expression vector, or also from viral particles purified from biological samples or in vitro propagation system.
  • polyprotein NS3/NS4 and the polypeptide NS5b of the invention of recombinant origin can also be obtained by the genetic engineering technique, which comprises the steps of:
  • nucleotide sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b can be prepared by chemical synthesis in conjunction with a genetic engineering approach or by genetic engineering alone, using the techniques well known to a person skilled in the art and described for example in Sambrook J. et al., Molecular Cloning: A Laboratory Manual, 1989.
  • nucleotide sequences coding for the polyprotein NS3/NS4 and the polypeptide NS5b can be inserted into expression vectors in a suitable expression system, in order to obtain the peptide composition of the invention.
  • nucleotide sequences can be inserted into a single expression vector or into two different expression vectors.
  • sequence coding for the polyprotein NS3/NS4 is inserted into one of the two vectors and the sequence coding for the polypeptide NS5b is inserted into the other vector, these two vectors being either identical or different in nature.
  • another object of the invention is the expression vectors comprising a nucleotide sequence coding for the polyprotein NS3/NS4 and a nucleotide sequence coding for the polypeptide NS5b, as well as the means necessary to its expression.
  • peptide By means necessary to the expression of a peptide is meant, the term peptide being used for any peptide molecule, such as protein, polyprotein, polypeptide, etc., any means that make it possible to obtain the peptide, such as in particular a promoter, a transcription terminator, a replication origin and preferably a selection marker.
  • the means necessary to the expression of a peptide are operationally linked to the nucleic acid sequence coding for the peptide of interest.
  • operationally linked is meant a juxtaposition of said elements necessary to the expression and of the gene coding for the peptide of interest, which are in a relationship such that it is possible for them to function in an expected manner.
  • additional bases can exist between the promoter and the gene of interest to the extent that their functional relationship is preserved.
  • the means necessary to the expression of a peptide can be homologous means, i.e. included in the genome of the vector used, or be heterologous. In the latter case, said means are cloned with the peptide of interest to be expressed.
  • heterologous promoters include (i) the viral promoters such as the SV40 promoter (simian virus 40), the promoter of the thymidine-kinase gene of the herpes simplex virus (TK-HSV-1), the LTR of the Rous sarcoma virus (RSV), the immediate first promoter of the cytomegalovirus (CMV) and the adenovirus major last promoter (MLP), as well as (ii) any cell promoter that controls the transcription of the genes coding for peptides in upper eukaryotes, such as the constitutive promoter of the diphosphoglycerate-kinase gene (PGK) (Adra et al., 1987, Gene, 60: 65-74), the promoter of the liver-specific alpha-1 antitrypsin and FIX genes and the SM22 promoter specific to the smooth muscle cells (Moessler et al., 1996, Development, 122: 2415-2425).
  • the viral promoters
  • nucleotide sequences coding for said polyprotein NS3/NS4 and said polypeptide NS5b originate from different genotypes.
  • nucleotide sequences coding for said polyprotein and said polypeptide originate from a virus of the same genotype, preferably genotype 1b.
  • nucleotide sequence is meant all the sequences coding for the native polyprotein NS3/NS4 and the native polypeptide NS5b, as well as for their analogues, muteins and homologues, as defined previously.
  • Said sequences contained in the expression vector can be directly interlinked under the control of a single promoter and/or of a single expression-regulating element, or they can be separate, each being dependent on expression promoters and/or regulators that are independent identical or different.
  • expression vectors that are suitable for the purposes of the invention, there can be mentioned for example plasmids, adenovirus-type viral vectors, poxviruses, vaccinia viruses, baculoviruses, salmonella-type bacterial vectors, BCG.
  • Adenoviruses have been detected in numerous animal species, do not integrate and are only slightly pathogenic. They are capable of infecting a variety of cell types, cells in division and cells at rest. They possess a natural tropism for the bronchial epithelia. Moreover, they have been used as live enteric vaccines for many years with an excellent safety profile. Finally, they can easily be made to grow and be purified in large amounts. These characteristics have meant that the adenoviruses are particularly appropriate for use as expression vectors and in particular as gene therapy vectors for therapeutic purposes and for vaccines.
  • the vector of the invention is an adenovirus.
  • adenoviruses to be used in the present invention can be derived from any source of human or animal origin, in particular of canine origin (for example CAV-1 or CAV-2; reference Genbank CAV1GENOM and CAV77082 respectively), of avian origin (reference Genbank AAVEDSDNA), of bovine origin (such as BAV3, Seshidhar Reddy et al., 1998, J. Virol., 72: 1394-1402), of ovine, feline, porcine origin, of simian origin, or from one of their hybrids. Any serotype can be used. However, adenoviruses of human origin are preferred and in particular adenovirus 5 (AdIV).
  • canine origin for example CAV-1 or CAV-2; reference Genbank CAV1GENOM and CAV77082 respectively
  • avian origin reference Genbank AAVEDSDNA
  • bovine origin such as BAV3, Seshidhar Reddy et al., 1998, J. Virol., 72: 1394-1402
  • viruses are available from the ATCC collections and have been the subject of numerous publications describing their sequence, their organization and their biology, which allows a person skilled in the art to use them easily.
  • sequence of the adenovirus type 5 is described in the Genbank database (M73260 and M29978) and is incorporated here by way of reference.
  • the genome of the adenovirus is constituted by a double-strand linear DNA molecule of approximately 36 kb carrying more than approximately 30 genes necessary for terminating the viral cycle.
  • the first genes are divided into 4 regions dispersed in the genome of the adenovirus (E1 to E4).
  • the E1, E2 and E4 regions are essential for viral replication.
  • the E3 region is considered as a non-essential region on the basis of the observation that mutant viruses appear naturally or the hybrid viruses having lost this E3 region continue to replicate like wild-type viruses in cultured cells (Kelly and Lewis, 1973, J. Virol., 12: 643-652).
  • the last genes (L1 to L5) mostly code for the structural proteins constituting the viral capsid.
  • the adenoviral genome carries at the two ends of the cis-acting regions essential for DNA replication, the 5′ and 3′ inverted terminal repeats (ITRs) and a packing sequence respectively.
  • the adenoviruses currently used in gene therapy protocols are stripped of the majority of the E1 region, which renders the viruses deficient at the level of their replication in order to avoid their dissemination in the environment and in the host organism. Moreover, most of the adenoviruses are also stripped of the E3 region in order to increase their cloning capacity.
  • the feasibility of gene transfer using these vectors has been demonstrated in a variety of tissues in vivo (see for example Yei et al., 1994, Hum. Gene Ther.,5: 731-744; Dai et al., 1995, Proc. Natl. Acad Sci. USA, 92: 1401-1405; U.S. Pat. No. 6,099,831; and U.S. Pat. No. 6,013,638).
  • the promoters used in the adenoviruses as expression vectors are heterologous promoters such as the CMV and SV40 promoters.
  • the CMV promoter is the promoter of the polyprotein NS3/NS4 and the expression vector comprises as nucleotide sequence coding for said polyprotein the expression cassette CMV-NS3-NS4.
  • expression cassette is meant a DNA sequence containing a promoter and an open reading frame for the expression of the peptide of interest, to be inserted into a vector.
  • the SV40 promoter is the promoter of the polypeptide NS5b and the expression vector comprises as nucleotide sequence coding for said polypeptide the expression cassette SV40-NS5b.
  • the genome of the adenovirus is modified so as to replace the EI region by the expression cassette CMV-NS3-NS4 and to replace the E3 region by the expression cassette SV40-NS5b.
  • Another expression vector particularly appropriate for the purposes of the invention is a poxvirus, which constitutes another embodiment of the invention.
  • the poxviruses constitute a group of enveloped complex viruses, differing principally in their unusual morphology, their large DNA genome and their cytoplasmic replication site.
  • the genome of several elements of the poxviridae comprising the Copenhagen strain of the vaccinia virus (VV) (Goebel et al., 1990, Virol. 179: 247-266 and 517-563) and the modified vaccinia virus Ankara (MVA) strain (Antoine et al., 1998, Virol., 244: 635-396), has been mapped and sequenced.
  • the VV strain possesses a double-strand DNA genome of approximately 192 kb coding for approximately 200 proteins approximately 100 of which are involved in the assembly of the virus.
  • the MVA strain is a highly attenuated strain of vaccinia virus, generated by more than 500 passages in series of the vaccinia virus Ankara strain (CVA) over chicken embryo fibroblasts (Mayr et al., 1975, Infection, 3: 6-16).
  • the MVA virus has been deposited in the Collection Nationale de Cultures de Microorganismes (CNCM) under Number I-721.
  • CNCM Collection Nationale de Cultures de Microorganismes
  • the determination of the complete sequence of the MVA genome and comparison with that of the VV allows precise identification of the alterations that have appeared in the viral genome and the definition of seven deletions (I to VII) and of numerous mutations leading to fragmented open reading frames (Antoine et al., 1998, Virology, 244: 365-396).
  • poxviruses that are appropriate for the purposes of the invention include duck pox, fowl pox, cow pox, entomopox, monkey pox, swine pox and penguin pox.
  • the poxvirus is found in two morphologically distinct forms, called intracellular mature virus (IMV) and enveloped extracellular virus (EEV).
  • IMV intracellular mature virus
  • EMV enveloped extracellular virus
  • the poxvirus used as an expression vector of the invention has at least one of the following characteristics, taken alone or in combination:
  • the means necessary to their expression are homologues.
  • the expression of NS3/NS4 can be for example under the control of the promoter ph5r so that the corresponding expression cassette is ph5r-NS3-NS4, and the expression of NS5b can be for example under the control of the promoter p7.5 so that the corresponding expression cassette is p7.5-NS5b, and vice versa.
  • the two said expression cassettes are oriented in the same direction.
  • they are oriented in the opposite direction.
  • the expression cassettes are inserted into the genome of the poxvirus in a manner known to a person skilled in the art, as indicated previously.
  • the vectors of the invention can also comprise sequences necessary for targeting peptides towards particular cell compartments.
  • An example of targeting can be the targeting towards the endoplasmic reticulum obtained using address sequences of the leader sequence type originating from the protein E3 of the adenovirus (Ciernik I. F., et al., The Journal of Immunology, 1999, 162, 3915-3925).
  • They can also comprise sequences necessary for targeting towards the dendritic cells and for targeting at the membrane of the cells.
  • An object of the invention is also the microorganisms and the eukaryotic cells transformed by an expression vector of the invention.
  • yeasts such as those of the following families: Saccharomyces, Schizosaccharomyces, Kluveromyces, Pichia, Hanseluna, Yarrowia, Schwantomyces, Zygosaccharomyces, Saccharomyces cerevisiae, Saccharomyces carlsbergensis and Kluveromyces lactis being preferred; and the bacteria, such as E. coli and those of the following families: Lactobacillus, Lactococcus, Salmonella, Streptococcus, Bacillus and Streptomyces.
  • eukaryotic cells By way of examples of eukaryotic cells, there can be mentioned cells originating from animals such as mammals, reptiles, insects-and equivalent.
  • the preferred eukaryotic cells are cells originating from the Chinese hamster (CHO cells), monkey (COS and Vero cells), baby hamster kidney (BHK cells), pig kidney (PK 15 cells) and rabbit kidney (RK13 cells), human osteosarcoma cell lines (143 B), HeLa human cell lines and the human hepatoma cell lines (Hep G2-type cells), as well as insect cell lines (for example of Spodoptera frugiperda ).
  • the host cells can be provided in cultures in suspension or in flasks, in tissue cultures, organ cultures and equivalent.
  • the host cells can also be transgenic animals.
  • the invention also relates to antibodies directed against one of the peptide compositions of the invention as defined previously or against one of the expression vectors of the invention as defined previously.
  • the antibodies according to the invention are either polyclonal or monoclonal antibodies.
  • polyclonal antibodies can be obtained by immunization of an animal with the peptide composition of the invention or with the vector of the invention as “antigen of interest”, followed by the recovery of the antibodies sought in purified form, by sampling the serum of said animal, and separation of said antibodies from the other constituents of the serum, in particular by affinity chromatography on a column to which is fixed an antigen specifically recognized by the antibodies, in particular a viral antigen of interest.
  • the monoclonal antibodies can be obtained by the hybridomas technique the general principle of which is recalled hereafter.
  • an animal In a first step, an animal, generally a mouse, (or cells in culture within the framework of in vitro immunizations) is immunized with the peptide composition of the invention or with the vector of the invention as “antigen of interest”, the B lymphocytes of which are then capable of producing antibodies against said antigen. These antibody-producing lymphocytes are then fused with “immortal” myelomatous cells (murine in the example) in order to produce hybridomas. From the thus-obtained heterogeneous mixture of cells, a selection is then made of cells capable of producing a particular antibody and multiplying indefinitely.
  • Each hybridoma is multiplied in clone form, each leading to the production of a monoclonal antibody the recognition properties of which vis-à-vis the antigen of interest can be tested for example by ELISA, by immunotransfer in one or two dimensions, by immunofluorescence, or using a biocaptor.
  • the monoclonal antibodies thus selected are subsequently purified in particular according to the affinity chromatography technique described above.
  • the peptide compositions, the expression vectors, the nucleotide sequences coding for said polyprotein NS3/NS4 and said polypeptide NS5b, as well as the antibodies of the invention are particularly effective for the inhibition, prevention and control of the infection of patients carrying the HCV virus, so that their use for the preparation of a medicament constitutes another object of the invention.
  • the present invention also relates to a pharmaceutical composition, in particular a vaccine, containing as active ingredient the peptide composition of the invention, or an expression vector of the invention, or an expression vector comprising a nucleotide sequence coding for the polyprotein NS3/NS4 with an expression vector comprising a nucleotide sequence coding for the polypeptide NS5b, or the nucleotide sequences coding for said polyprotein NS3/NS4 and said polypeptide NS5b, said nucleotide sequences corresponding to the sequences contained in the expression vectors of the invention, placed under the control of elements necessary to an expression constitutive of and/or inducible from said peptides, or at least one of the antibodies of the invention.
  • elements necessary to an expression constitutive of the peptides is meant a promoter that is ubiquitous or specific to the eukaryotic cells.
  • the pharmaceutical composition also contains a pharmaceutically appropriate vehicle.
  • a pharmaceutically appropriate vehicle e.g., a pharmaceutically appropriate vehicle
  • a person skilled in the art will easily determine the nature of the pharmaceutically appropriate vehicle and the quantity of polypeptides to be used as a function of the constituents of the pharmaceutical composition.
  • the quantity and nature of the pharmaceutically appropriate vehicle can be easily determined by a person skilled in the art. They are chosen according to the desired pharmaceutical form and method of administration.
  • compositions of the invention are appropriate for oral, sublingual, sub-cutaneous, intramuscular, intravenous, topical, local, intratracheal, intranasal, transdermal, rectal, intraocular, intra-auricular administration, said active ingredient being able to be administrated in a unitary dosage form of administration.
  • the unitary dosage forms of administration can be for example tablets, gelatin capsules, granules, powders, solutions or injectable oral suspensions, transdermal patches, forms of sublingual, buccal, intratracheal, intraocular, intranasal, intra-auricular or by inhalation administration, forms of topical, transdermal, sub-cutaneous, intramuscular or intravenous administration, forms of rectal administration, or implants.
  • transdermal patches forms of sublingual, buccal, intratracheal, intraocular, intranasal, intra-auricular or by inhalation administration
  • forms of topical, transdermal, sub-cutaneous, intramuscular or intravenous administration forms of rectal administration, or implants.
  • creams, gels, ointments, lotions or collyriums can be envisaged.
  • Said unitary dosage forms are dosed in order to allow daily administration of 0.001 to 10 mg of active ingredient per kg of body weight, according to the galenic form.
  • the dosage appropriate to each patient is determined by the doctor according to the method of administration, the weight and the response of the patient.
  • the present invention also relates to a method of treatment of the pathologies associated with the hepatitis C virus, which comprises the administration, to a patient, of an effective dose of a medicament of the invention.
  • compositions of the invention preferably contain as active ingredient one of the vectors of the invention or an expression, vector comprising a nucleotide sequence coding for the polyprotein NS3/NS4 with an expression vector comprising a nucleotide sequence coding for the polypeptide NS5b, so that they are useful in prophylactic and therapeutic vaccination.
  • Prophylactic and therapeutic vaccination can be implemented by injection of a vaccine based on one or more expression vectors of the invention, to the extent that the expression vector or vectors finally code for the polyprotein NS3/NS4 and for the polypeptide NS5b as active ingredient, said injection being or being not followed by boosters. It can also be implemented by injecting two different types of expression vectors of the invention, firstly an adenovirus, then a poxvirus, simultaneously or at different times, and vice versa.
  • vectors can be contained in a pharmaceutical kit.
  • kits in particular vaccinal, comprising at least one expression vector comprising a nucleotide sequence coding for the polyprotein NS3/NS4 and at least one expression vector comprising a nucleotide sequence coding for the polypeptide NS5b.
  • kits in particular vaccinal, comprising at least one expression vector of adenovirus type as defined previously and/or at least one expression vector of poxvirus type as defined previously.
  • Prophylactic and therapeutic vaccination can also be implemented by injection of a vaccine based on at least one expression vector of the invention, or an expression vector comprising a nucleotide sequence coding for the polyprotein NS3/NS4 with an expression vector comprising a nucleotide sequence coding for the polypeptide NS5b, and at least one pharmaceutical composition of the invention constituted by the peptide composition of the invention or the antibodies of the invention.
  • a vaccine based on at least one expression vector of the invention, or an expression vector comprising a nucleotide sequence coding for the polyprotein NS3/NS4 with an expression vector comprising a nucleotide sequence coding for the polypeptide NS5b, and at least one nucleotide sequence coding for the polyprotein NS3/NS4 and for the polypeptide NS5b.
  • kits in particular vaccinal, comprising at least one expression vector of the invention, or an expression vector comprising a nucleotide sequence coding for the polyprotein NS3/NS4 with an expression vector comprising a nucleotide sequence coding for the polypeptide NS5b, and at least one pharmaceutical composition of the invention or at least one nucleotide sequence coding for the polyprotein NS3/NS4 and for the polypeptide NS5b.
  • FIGS. 1A to 1 K represents the maps of the different plasmids used for obtaining an adenovirus AdNS3NS4NS5b according to the invention, on which are indicated the sites of the different restriction enzymes and the location of the sequence fragments coding for NS3/NS4 and for NS5b,
  • FIGS. 2A to 2 H represents the maps of the different plasmids used for obtaining a poxvirus MAV NS3NS4NS5b according to the invention, on which are indicated the sites of the different restriction enzymes and the location of the sequence fragments coding for NS3/NS4 and pour NS5b,
  • FIG. 3 gives the cell response induced by the adenovirus AdNS3NS4, either according to the CTL test ( FIG. 3A ) where the epitope GLL was used for stimulating the splenocytes in culture and for loading the CTL targets and the result of which is expressed as a specific lysis percentage as a function of the effector/target ratio, or according to the ELISPOT test ( FIG. 3B ), specific to the epitope GLL, where the result is given in numbers of spots/10 6 cells,
  • FIG. 4 gives the cell response induced by the adenovirus AdNS5b according to the test ELISPOT, specific to the epitopes ALY and KLP,
  • FIG. 5 gives the cell response induced by the adenovirus AdCEIE2 according to the CTL test where the epitope DLM was used for stimulating the splenocytes in culture and for loading the targets of the CTL and the result of which is expressed as a specific lysis percentage as a function of the effector/target ratio,
  • FIG. 6 gives the titre of the recombinant vaccinia virus, resulting from the trial test, in pfu/ml/mg ovary, for the 4 groups of 8 mice immunized by the different combinations of adenovirus: AdNS3NS4+AdNS5b (1st group), the adenoviruses AdNS3NS4+AdNS5b+AdNS5a (2nd group), the adenoviruses AdNS3NS4+AdNS5b+AdCEIE2 (3rd group) and the adenovirus Ad ⁇ Gal (4th group) and
  • FIG. 7 gives the titre of the recombinant vaccinia virus, resulting from the trial test, in pfu/ml/mg ovary, for the 3 groups of 8 mice immunized by the following different combinations of adenovirus: AdNS3NS4NS5b (1st group), AdNS3NS4+AdNS5b (2nd group) and Ad ⁇ Gal (3rd group).
  • the recombinant adenoviruses are generated by transfection (CaPO3) of the complementation line 293 (Graham, Smiley, et al. 1977) after linearization of the genomes by PacI.
  • the recombinant viruses propagate and are amplified on this same line, and their purification is carried out from the infected cells.
  • the cells are recovered by centrifugation (1500 rpm, 10 minutes) and lysed by 3 freeze/thaw cycles.
  • the cell lysate is clarified by two centrifugations (2000 rpm, 10 minutes; 8000 rpm, 15 minutes), then purified by two successive ultracentrifugations.
  • the first is carried out on a Caesium Chloride gradient (densities 1.4 and 1.25) at 30,000 rpm for 1 hour.
  • the second is carried out on a Caesium Chloride cushion (density 1.34) at 35,000 rpm for 18 hours.
  • the phases containing the virions are removed and diluted by half in a 60% saccharose buffer.
  • the viral suspensions are then dialysed against formulation buffer (for 10 litres: 3423 g of saccharose; 12.11 g of Tris; 2.033 g of MgCl 2 ; 87.7 g of NaCl), then aliquoted.
  • This adenovirus allows the expression of the gene coding for the polyprotein NS3/NS4 (SEQ ID No. 1 and 2) under the control of the CMV promoter.
  • oligonucleotides were used: olV166: (SEQ ID No. 9) 5′-GGG GGG GCT ATG GCG CCT ATC ACG GCC TA-3′ olV171: (SEQ ID No. 10) 5′-GGG GGG ACG CGT TTA GCA TGG CGT GGA GCA GT-3′
  • the PCR conditions were the following:
  • Plasmid maxi-preparation (Qiagen, according to manufacturer's protocol) of a positive clone after restriction analysis
  • strain BJ Bacterial transformation
  • This adenovirus allows the expression of the gene coding for the polyprotein NS3/NS4 under the control of the CMV promoter and the expression of the gene coding for the polypeptide NS5b under the control of the SV40 promoter.
  • PCR amplification of the nucleotide sequence coding for the protein NS5b (SEQ ID No. 3 and 4) using the following nucleotides: olV212: (SEQ ID No. 13) 5′-GGG GGG TCT AGA ATG TCA ATG TCC TAC ACA TGG AC-3′ olV218: (SEQ ID No. 14) 5′-GGG GGG TCT AGA TTA CCG GTT GGG GAG CAG GT-3′ and according to the procedure described in point 2.1 above, except that a temperature of 60° C. instead of 62° C. was used
  • strain BJ Bacterial transformation
  • HCV antigens encoded by the adenoviruses AdNS3NS4, AdNS5b and AdNS3NS4NS5b was verified by Western blot after infection of Huh7 cells.
  • the strain Modified Virus Ankara MVATG N33 was supplied by TRANSGENE S. A. (Strasbourg, France).
  • Plasmid maxi-preparation (Qiagen) of a positive clone after restriction analysis (EcoRV+HindIII (in React 2 Buffer, Invitrogen): fragments of 246, 439, 476, 826 and 2789 pb; SacI: fragments of 915 and 3861 pb)
  • oligonucleotides were used: olV225: (SEQ ID No. 15) 5′-GGG GGG CTG CAG ATG GCG CCT ATC ACG GCC TA-3′ olV226: (SEQ ID No. 16) 5′-GGG GGG TCT AGA TTA GCA TGG CGT GGA GCA GT-3′ and according to the procedure described in Example 1, point 2.1 above, except that a temperature of 52° C. instead of 62° C. was used.
  • olV227 (SEQ ID No. 17) 5′-GGG GGG GTC GAC ATG TCA ATG TCC TAC ACA TGG AC-3′
  • olV228 (SEQ ID No. 18) 5′-GGG GGG GCA TGC TTA CCG GTT GGG GAG CAG GT-3′ and according to the procedure described in Example 1, point 2.1 above, except that a temperature of 52° C. instead of 62° C. was used.
  • HLA-A2.1 transgenic mice were immunized, once, by intramuscular injection of at least one adenovirus chosen from the following adenoviruses:
  • AdNS3NS4 prepared in Example 1 above (point 2.3),
  • AdNS5 prepared in Example 1 above (point 3.3),
  • AdNS5a prepare according to the procedure of Example 1, point 2, except that the following nucleotide primers were used in order to amplify the nucleotide sequence coding for the polypeptide NS5a (SEQ ID No. 5 and 6): olV172: (SEQ ID No. 20) 5′-GGG GGG GGT ACC ATG TCC GGC TCG TGG CTA AGG-3′, olV173: (SEQ ID No. 21) 5′-GGG GGG TCT AGA TTA GCA GCA GAC GAT GTC GTC-3′, in the PCR the temperature of 62° C.
  • AdCE1E2 according to the procedure of Example 1, point 2, except that the following nucleotide primers were used in order to amplify the nucleotide sequence coding for the core-E1-E2 polyprotein (also called CE1CE2) (SEQ ID No. 7 and 8): olV62: (SEQ ID No. 22) 5′-GGG GGG GCT AGC ATG AGC ACA AAT CCT AAA CCT-3′, olV68: (SEQ ID No. 23) 5′-GGG GGG TCT AGA TCA GGC CTC AGC CTG GGC TAT-3′, in the PCR the temperature of 62° C.
  • AdNS3NS4NS5b prepared in Example 1 above (point 3) and
  • Ad ⁇ Gal (Transgene), according to the following protocol:
  • spleen cells splenocytes
  • these splenocytes were cultured on 24-well plates in the presence of:
  • the specific cytotoxic activity of the effector cells was determined by measuring, after 4 hours of incubation with the target cells, Cr 51 released following lysis of the target cells using a ⁇ -Cobra II counting apparatus (Packard, Rungis, France) The maximum spontaneous release from wells containing either medium alone, or lysis buffer (HCl IN) was determined. The specific percentage of cytotoxicity was calculated by the formula:
  • the epitope-specific lysis was determined by the difference between the percentage of specific lysis obtained in the presence or in the absence of said epitopes.
  • the ELISPOT test was carried out by culturing the splenocytes for 48 hours in Multiscreen 96-well plates (Millipore) previously coated with anti-interferon gamma antibodies (IFN ⁇ ) (IO ⁇ g/ml final).
  • the splenocytes were cultured in the presence of 10 ⁇ M of the appropriate epitopes, as indicated above, and of 10 U of murine recombinant interleukin 2 per ml in ⁇ MEM.
  • the splenocytes were cultured in the presence of concanavalin A (5 ⁇ g/ml).
  • the splenocytes were cultured either in the presence of a non-specific peptide belonging to the capsid protein of HCV, of sequence DLMGYIPLV (also called irrelevant peptide), or in medium alone without epitope.
  • the wells were washed three times, with 0.05% PBS-Tween then PBS respectively, an operation followed by incubation for 2 hours with anti-IFN ⁇ antibodies from biotinylated mice. After washing, the wells were incubated for 1 hour with a streptavidine-horseradish peroxidase conjugate and the enzymatic activity was developed by degradation of the AEC (aminoethylcarbazole) substrate. The spots obtained were counted using a Zeiss ELISpot reader (Zeiss microscope in conjunction with the KS-ELISpot software).
  • AdNS3NS4 clearly induces a cell-mediated response specific of the expressed antigens, as illustrated in FIGS. 3A and 3B by the detection of T lymphocytes specific to the epitope GLL contained in NS3.
  • AdNS5b clearly induces a cell-mediated response specific of the expressed antigens, as illustrated in FIG. 4 by the detection of T lymphocytes specific to the epitope ALY and KLQ contained in NS5b.
  • AdCEIE2 clearly induces a cell-mediated response specific of the expressed antigens, as illustrated in FIG. 5 by the detection of T lymphocytes specific to the epitope DLM contained in the Core protein.
  • mice not being directly infectable by HCV, in order to link the induction of a specific immune response and resistance to an infection, we used a recombinant vaccinia virus (strain WR) coding for the non-structural proteins of HCV (NS2 to NS5b) in order to carry out this trial.
  • This recombinant vaccinia virus after intra-peritoneal injection of 10 7 pfu in the mouse, will be replicated in the animal. The replication of this virus induces an immune response both specific to the vaccinia antigens and specific to the HCV antigens, as it also expresses the NS proteins of HCV.
  • This specific response to the HCV antigens will be all the more effective and vigorous as the mice will have already received a vaccine expressing the HCV antigens.
  • the more the effective vaccination in the present case carried out with the recombinant adenoviruses
  • the stronger will be the anti-HCV response generated after trial by the recombinant vaccinia virus and, consequently, the more the mice are “protected”against this trial.
  • the lower the residual vaccinia virus count in the mice the more effective the protection or the neutralization due to the vaccination has been.
  • the neutralization of the vaccinia virus reflects both the cell response induced by the HCV proteins and by the vaccinia proteins.
  • the neutralization is evaluated by titration of the residual vaccinia virus from the ovaries of the animals as follows: the ovaries are removed 4 days post-trial, sonicated, freeze-thawed 3 times then after centrifugation, successive dilutions of supernatant are titrated according to the lysis plaque technique (Murata et al., PNAS, vol. 100, p. 6753-6758) on Hutk-cells. The viral titres are determined in pfu/ml/mg of ovary.
  • the recombinant virus titre of the vaccine was determined for 4 groups of 8 mice immunized by the following combinations of adenoviruses: AdNS3NS4+AdNS5b (1st group), AdNS3NS4+AdNS5b+AdNS5a (2nd group), AdNS3NS4+AdNS5b+AdCEIE2 (3rd group) and Ad ⁇ Gal (4th group).
  • results, given in FIG. 6 are treated statistically on the basis of the Wilcoxon Mann-Whitney non-parametric test (Méthodes Statistiques à l'usage des funds et des biologistes, Collection Statistique en Biologie et en Médecine, Flammarion Medecine Sciences, (D. Schwarz), 1977), which is based on a comparison of the averages, and allows the comparison of the values of two independent samples x and y.
  • the values in Table 1 above show that only a vaccination of the mice by a combination of the Adenoviruses NS3NS4 and adenovirus NS5b is capable of inducing a significant neutralization of the replication of the vaccinia virus used in the trial with respect to the group of control mice vaccinated by Ad ⁇ Gal.
  • the recombinant vaccinia virus titre was determined for 3 groups of 8 mice immunized by the following combinations of adenoviruses: AdNS3NS4AdNS5b (1st group), AdNS3NS4+AdNS5b (2nd group), and Ad ⁇ Gal (3rd group).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
US10/559,431 2003-06-05 2004-06-04 Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use Abandoned US20060134065A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US11/723,638 US7695960B2 (en) 2003-06-05 2007-03-21 Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
US12/472,330 US8057162B2 (en) 2003-06-05 2009-05-26 Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
US13/241,578 US8541004B2 (en) 2003-06-05 2011-09-23 Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR03/06772 2003-06-05
FR0306772A FR2855758B1 (fr) 2003-06-05 2003-06-05 Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique
PCT/FR2004/050214 WO2004111082A2 (fr) 2003-06-05 2004-06-04 Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2004/050214 A-371-Of-International WO2004111082A2 (fr) 2003-06-05 2004-06-04 Composition comprenant la polyproteine ns3/ns4 et le polypeptide ns5b du vhc, vecteurs d'expression incluant les sequences nucleiques correspondantes et leur utilisation en therapeutique

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/723,638 Continuation-In-Part US7695960B2 (en) 2003-06-05 2007-03-21 Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
US12/472,330 Continuation US8057162B2 (en) 2003-06-05 2009-05-26 Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use

Publications (1)

Publication Number Publication Date
US20060134065A1 true US20060134065A1 (en) 2006-06-22

Family

ID=33443147

Family Applications (3)

Application Number Title Priority Date Filing Date
US10/559,431 Abandoned US20060134065A1 (en) 2003-06-05 2004-06-04 Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
US12/472,330 Expired - Fee Related US8057162B2 (en) 2003-06-05 2009-05-26 Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
US13/241,578 Expired - Fee Related US8541004B2 (en) 2003-06-05 2011-09-23 Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/472,330 Expired - Fee Related US8057162B2 (en) 2003-06-05 2009-05-26 Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
US13/241,578 Expired - Fee Related US8541004B2 (en) 2003-06-05 2011-09-23 Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use

Country Status (21)

Country Link
US (3) US20060134065A1 (fr)
EP (1) EP1629091B1 (fr)
JP (1) JP4625803B2 (fr)
KR (1) KR101158741B1 (fr)
CN (1) CN100506980C (fr)
AT (1) ATE508184T1 (fr)
AU (1) AU2004247457B2 (fr)
BR (1) BRPI0411011A (fr)
CA (1) CA2528240C (fr)
CY (1) CY1112081T1 (fr)
DE (1) DE602004032536D1 (fr)
DK (1) DK1629091T3 (fr)
ES (1) ES2362578T3 (fr)
FR (1) FR2855758B1 (fr)
HK (1) HK1092498A1 (fr)
MX (1) MXPA05013127A (fr)
PL (1) PL1629091T3 (fr)
PT (1) PT1629091E (fr)
SI (1) SI1629091T1 (fr)
WO (1) WO2004111082A2 (fr)
ZA (1) ZA200509937B (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220532A1 (en) * 2005-06-13 2009-09-03 Claude Leclerc Agents and methods based on the use of the eda domian of fibronectin
EP2267120A1 (fr) * 2008-03-07 2010-12-29 Tokyo Metropolitan Organization for Medical Research Virus recombinant de la vaccine ayant un gène du virus de l'hépatite c
AU2008228450B2 (en) * 2007-03-21 2012-11-29 Transgene Sa Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5b of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
US8609392B2 (en) 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
CN117379542A (zh) * 2023-09-27 2024-01-12 广州佰芮慷生物科技有限公司 一种用于预防多基因型丙型肝炎病毒的腺病毒载体疫苗

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6501990B1 (en) 1999-12-23 2002-12-31 Cardiac Pacemakers, Inc. Extendable and retractable lead having a snap-fit terminal connector
JP4761311B2 (ja) * 2004-04-30 2011-08-31 日本電気株式会社 Ｈｌａ結合性ペプチド、それをコードするｄｎａ断片および組み換えベクター
JP5188400B2 (ja) * 2006-03-09 2013-04-24 トランスジーン エス．エー． Ｃ型肝炎ウイルスの非構造融合タンパク質
CA2682935C (fr) 2007-04-11 2020-01-28 Thomson Licensing Procede et appareil pour ameliorer des effets video numeriques (dve)
WO2009079834A1 (fr) * 2007-12-18 2009-07-02 Peking University People's Hospital Vaccin anti-vhc et procédés de préparation et utilisations de celui-ci
NZ593749A (en) 2009-01-20 2012-05-25 Transgene Sa Soluble icam-1 as biomarker for prediction of therapeutic response
US20120028279A1 (en) 2009-03-24 2012-02-02 Bruce Acres Biomarker for monitoring patients
DK2452194T3 (en) 2009-07-10 2015-11-30 Transgene Sa Biomarker PATIENT SELECTION AND RELATED PRACTICES
TW201109440A (en) 2009-07-21 2011-03-16 Transgene Sa Enzymatic composition for the digestion of chicken embryos
CA2770075C (fr) * 2009-08-07 2021-08-24 Perrine Martin Composition pour le traitement d'une infection par le virus de l'hepatite b
WO2011073741A1 (fr) 2009-12-18 2011-06-23 Transgene Sa Procédé et système de traitement automatique de multiples mesures de paramètres biologiques quantifiables
DK3205353T3 (da) * 2011-03-21 2021-04-06 Altimmune Inc Hurtig- og langtidsvirkende immunologisk terapeutisk middel
TW201321016A (zh) 2011-09-29 2013-06-01 Transgene Sa 免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（二）
WO2013045658A1 (fr) 2011-09-29 2013-04-04 Transgene Sa Composition et régime d'immunothérapie pour le traitement d'une infection par le virus de l'hépatite c
WO2014009433A1 (fr) 2012-07-10 2014-01-16 Transgene Sa Facteur de ressuscitation de mycobactéries convenant comme adjuvant
TWI690322B (zh) 2012-10-02 2020-04-11 法商傳斯堅公司 含病毒的調配物及其使用
WO2014064534A2 (fr) 2012-10-05 2014-05-01 Chrontech Pharma Ab Aiguille d'injection, dispositif, compositions immunogènes et procédé d'utilisation
WO2016087457A1 (fr) 2014-12-01 2016-06-09 Transgene Sa Formulations liquides stables de virus de la vaccine
CA3023022A1 (fr) 2016-05-04 2017-11-09 Transgene Sa Polytherapie avec un ligand de tlr9 cpg
US20190328869A1 (en) 2016-10-10 2019-10-31 Transgene Sa Immunotherapeutic product and mdsc modulator combination therapy
EP3624845A1 (fr) 2017-05-15 2020-03-25 Janssen Vaccines & Prevention B.V. Composition contenant un virus stable
AU2018269319A1 (en) 2017-05-15 2019-11-07 Janssen Vaccines & Prevention B.V. Stable virus-containing composition
JP7437385B2 (ja) 2018-09-06 2024-02-22 バヴァリアン・ノルディック・アクティーゼルスカブ 保管が改善されたポックスウイルス組成物
EP4117722A1 (fr) 2020-03-12 2023-01-18 Bavarian Nordic A/S Compositions améliorant la stabilité du poxvirus

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312889B1 (en) * 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US6562346B1 (en) * 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
US6986892B1 (en) * 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002501737A (ja) 1998-01-30 2002-01-22 ザ・ジェネラル・ホスピタル・コーポレイション Ｃ型肝炎ウイルスの非構造蛋白質による遺伝的免疫感作
MY127037A (en) * 1999-07-12 2006-11-30 Saes Pure Gas Inc Gas purification system with an integrated hydrogen sorption and filter assembly
FR2839722A1 (fr) * 2002-05-17 2003-11-21 Bio Merieux Nouvelles compositions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
US7695960B2 (en) * 2003-06-05 2010-04-13 Transgene S.A. Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312889B1 (en) * 1990-04-04 2001-11-06 Chiron Corporation Combinations of hepatitis c virus (HCV) antigens for use in immunoassays for anti-HCV antibodies
US7052696B2 (en) * 1998-07-10 2006-05-30 The United States Of America As Represented By The Department Of Health And Human Services Antigenic epitopes and mosaic polypeptides of hepatitis C virus proteins
US6562346B1 (en) * 1999-10-27 2003-05-13 Chiron Corporation Activation of HCV-specific T cells
US7285539B2 (en) * 1999-10-27 2007-10-23 Chiron Corporation Activation of HCV-specific T cells
US6986892B1 (en) * 1999-11-24 2006-01-17 Chiron Corporation Immunogenic Hepatitis C virus non-structural polypeptides

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090220532A1 (en) * 2005-06-13 2009-09-03 Claude Leclerc Agents and methods based on the use of the eda domian of fibronectin
US9155783B2 (en) * 2005-06-13 2015-10-13 Proyecto De Biomedicina Cima, S.L. Agents and methods based on the use of the EDA domain of fibronectin
AU2008228450B2 (en) * 2007-03-21 2012-11-29 Transgene Sa Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5b of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
EP2267120A1 (fr) * 2008-03-07 2010-12-29 Tokyo Metropolitan Organization for Medical Research Virus recombinant de la vaccine ayant un gène du virus de l'hépatite c
EP2267120A4 (fr) * 2008-03-07 2012-06-27 Tokyo Metropolitan Inst Medical Science Virus recombinant de la vaccine ayant un gène du virus de l'hépatite c
US9000136B2 (en) 2008-03-07 2015-04-07 Tokyo Metropolitan Institute Of Medical Science Recombinant vaccinia virus having hepatitis C virus gene
US8609392B2 (en) 2009-05-12 2013-12-17 Transgene S.A. Method for orthopoxvirus production and purification
US9012198B2 (en) 2009-05-12 2015-04-21 Transgene S.A. Method for orthopoxvirus production and purification
CN117379542A (zh) * 2023-09-27 2024-01-12 广州佰芮慷生物科技有限公司 一种用于预防多基因型丙型肝炎病毒的腺病毒载体疫苗

Also Published As

Publication number Publication date
AU2004247457B2 (en) 2009-02-05
ES2362578T3 (es) 2011-07-07
WO2004111082A2 (fr) 2004-12-23
CA2528240A1 (fr) 2004-12-23
US20120039938A1 (en) 2012-02-16
HK1092498A1 (en) 2007-02-09
JP2007527207A (ja) 2007-09-27
ATE508184T1 (de) 2011-05-15
KR101158741B1 (ko) 2012-06-22
PT1629091E (pt) 2011-07-28
WO2004111082A3 (fr) 2005-02-17
AU2004247457A1 (en) 2004-12-23
DK1629091T3 (da) 2011-08-08
DE602004032536D1 (de) 2011-06-16
US8541004B2 (en) 2013-09-24
CN1833022A (zh) 2006-09-13
CN100506980C (zh) 2009-07-01
EP1629091A2 (fr) 2006-03-01
ZA200509937B (en) 2007-03-28
BRPI0411011A (pt) 2006-07-04
FR2855758A1 (fr) 2004-12-10
KR20060030476A (ko) 2006-04-10
US20100008941A1 (en) 2010-01-14
PL1629091T3 (pl) 2011-10-31
MXPA05013127A (es) 2006-05-25
CY1112081T1 (el) 2015-11-04
FR2855758B1 (fr) 2005-07-22
EP1629091B1 (fr) 2011-05-04
US8057162B2 (en) 2011-11-15
CA2528240C (fr) 2013-03-05
SI1629091T1 (sl) 2011-07-29
JP4625803B2 (ja) 2011-02-02

Similar Documents

Publication Publication Date Title
US8541004B2 (en) Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic use
JP5507265B2 (ja) ＨＣＶのポリタンパク質ＮＳ３／ＮＳ４及びポリペプチドＮＳ５ｂを含む組成物、対応する核酸配列を含む発現ベクター、及びそれらの治療的使用
WO2009131203A1 (fr) Acide nucléique contenant un gène chimérique issu du virus de l'hépatite de type c
US9057048B2 (en) Infectious hepatitis C virus—high producing HCV variants and use thereof
US8293528B2 (en) Peptide compositions and their use in particular in the preparation of pharmaceutical compositions active against the hepatitis C virus
JP5188400B2 (ja) Ｃ型肝炎ウイルスの非構造融合タンパク質
Seong et al. Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses
US20030021805A1 (en) Generation of HCV-like particles and chimeric HCV virus
US20060269562A1 (en) Polypeptides f' of the hepatitis c virus, t epitopeo, and the diagnostic and therapeutic applications thereof
JP2002501737A (ja) Ｃ型肝炎ウイルスの非構造蛋白質による遺伝的免疫感作
KR20070040814A (ko) 재조합 생 계두 바이러스 벡터 및 간염 ｃ 바이러스에 대한약학적 조성물로서의 이들의 용도

Legal Events

Date Code Title Description
AS Assignment

Owner name: TRANSGENE S.A., FRANCE

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FOURNILLIER, ANNE;INCHAUSPE, GENEVIEVE;ABRAHAM, JEAN-DANIEL;AND OTHERS;REEL/FRAME:017342/0649;SIGNING DATES FROM 20060120 TO 20060202

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:FOURNILLIER, ANNE;INCHAUSPE, GENEVIEVE;ABRAHAM, JEAN-DANIEL;AND OTHERS;REEL/FRAME:017342/0649;SIGNING DATES FROM 20060120 TO 20060202

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO PAY ISSUE FEE